Interim report January - March 2008

Key events in the first quarter
• LinkMed and SLS Venture co-invest in ONCOlog Medical
• ALMI Företagspartner becomes a new financer in Biovator
• IMED licenses world-leading technology from Medarex
• Agneta Edberg appointed new Chief Operating Officer (COO) and Jonas Graff-Lonnevig becomes new VP Financial Transactions with responsibility for exits

Key events after the period end
• Anders Karlsson appointed new CEO in AbSorber AB
• AbSorber is granted a patent in the U.S. for its AB0 column
• IMED’s basic patent is granted patent protection in Europe
• Birgitta Gunneflo was elected new board member by the 2008 AGM

Financial information January– March 2008
• Results from investing activities amounted to SEK 0 million (0)
• Other income amounted to SEK 1.1 million (1.2)
• Net Income/loss after tax amounted to SEK -3.5 million (-2.2)
• Earnings per share was SEK -0.40 (-0.25)
• Shareholders’ equity amounted to SEK 275.0 million compared to SEK 278.5 million at the year-end
• Shareholders’ equity per share was SEK 31.38, compared to SEK 31.93 at the year-end
• Equity/assets ratio was 98 percent, the same as at the year-end
• Liquid funds were SEK 112.1 million, compared to SEK 125.2 million at the year-end.

CEO Ingemar Lagerlöf’s comments on the first quarter 2008:
”With a stronger organization now in place, we have started exit preparations for a few of our portfolio companies. Following ONCOlog Medical’s successes last year, SLS Venture is a new partner and the company is intensifying commercialization of its products. The first quarter was intensive and I expect a continued high tempo for the rest of 2008. ”


For additional information please contact:
Ingemar Lagerlöf, CEO, cell: +46 (0)70 873 2733 or email ingemar.lagerlof@linkmed.se
Okee Williams, Portfolio Manager, cell: +46 (0)70 600 5364 or email okee.williams@linkmed.se